Farxiga Generic: Availability, Cost & Alternatives (2026)

At a glance

• Generic dapagliflozin / marketed in the U.S. by multiple manufacturers [2]
• Brand Farxiga / NDA 202293; approved 2014-01-08 [1]
• Labeled uses / CKD, heart failure, HF hospitalization in type 2 diabetes, glycemic control [2]
• Dose / 5 mg daily start for glycemic control; 10 mg daily for other uses [2]
• Combinations / Xigduo XR and dapagliflozin/saxagliptin [2]
• DAPA-CKD / 9.2% vs 14.5% primary composite (HR 0.61) [3]

Is generic dapagliflozin available in 2026?

Yes. Generic dapagliflozin tablets from multiple manufacturers are marketed in the U.S. [2]. Brand Farxiga is marketed under NDA 202293, first approved 2014-01-08; its current label is effective 2026-06-03 [1][2].

What does the Farxiga label cover?

The Farxiga label lists four uses: chronic kidney disease at risk of progression, heart failure, heart-failure hospitalization risk in type 2 diabetes with cardiovascular disease or multiple risk factors, and glycemic control in type 2 diabetes [2]. The label says to start at 5 mg once daily for glycemic control, which may be increased to 10 mg; for the other indications the recommended dose is 10 mg once daily [2]. It is not recommended for glycemic control when eGFR is under 45, and it has no weight-loss indication [2].

What do the trials show for dapagliflozin?

DAPA-HF randomized 4,744 adults with heart failure and ejection fraction 40% or less; worsening heart failure or cardiovascular death occurred in 16.3% vs 21.2% (HR 0.74, 0.65 to 0.85) over a median 18.2 months [5]. DAPA-CKD randomized 4,304 adults with chronic kidney disease; the primary composite occurred in 9.2% vs 14.5% (HR 0.61, 0.51 to 0.72), and the trial stopped early for efficacy [3]. DECLARE-TIMI 58 found no significant reduction in major adverse cardiovascular events (8.8% vs 9.4%; HR 0.93, 0.84 to 1.03) but a lower rate of cardiovascular death or heart-failure hospitalization (4.9% vs 5.8%; HR 0.83), driven by heart-failure hospitalization [4]. The label warns of ketoacidosis (which can present with glucose under 250 mg/dL), volume depletion, genitourinary infections including Fournier gangrene, and hypoglycemia with insulin or a secretagogue [2].

What should a cost comparison include?

Match the exact product and indication first: brand Farxiga, generic dapagliflozin, or a combination. Xigduo XR contains metformin and has its own label with its own warnings, so it is a different product from a dapagliflozin-only tablet. After that, compare the pharmacy cash price and plan formulary for that exact product.

Frequently asked questions

›Is generic dapagliflozin available in the U.S. in 2026?

Yes. Generic dapagliflozin tablets from multiple manufacturers are marketed in the U.S. [2].

›Does generic dapagliflozin cost less than Farxiga?

FDA labeling does not state prices or copays, so a price difference cannot be quoted here. Compare the cash price and plan coverage for each product [2][1].

›What are the alternatives to Farxiga?

Generic dapagliflozin tablets are marketed alongside brand Farxiga. Xigduo XR and a dapagliflozin/saxagliptin tablet are combination products with their own labels [2].

›Is Farxiga approved for weight loss?

No. The Farxiga label has no weight-management indication; its uses are CKD, heart failure, heart-failure hospitalization risk in type 2 diabetes with cardiovascular disease or risk factors, and glycemic control in type 2 diabetes [2].

›Does Farxiga work for CKD without diabetes?

The CKD indication does not require diabetes. DAPA-CKD included adults with and without type 2 diabetes and found fewer primary composite events with dapagliflozin (9.2% vs 14.5%; HR 0.61) [2][3].

References

1. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
2. U.S. National Library of Medicine, DailyMed. Farxiga tablets (AstraZeneca) (dapagliflozin) prescribing information. Farxiga tablets (AstraZeneca) (dapagliflozin) label
3. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. Dapagliflozin in Patients with Chronic Kidney Disease
4. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
5. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction